Healthy Aging / Longevity Stack

Best-in-class: Healthy Aging Bundle

Thorne's healthy-aging bundle -- a box of separate products rather than one formula, sold against the biology of aging. Thorne decides what ships in it and can change that without notice, so the contents are not listed here.

How Healthy Aging / Longevity Stack actually works

Bundles the better-evidenced components of the longevity category — typically an NAD+ precursor, a polyphenol, CoQ10 or a mitochondrial support, and the vitamin D and omega-3 base that actually has mortality data behind it. Each acts on a different hallmark of ageing, which is the argument for combining rather than choosing.

Where to get Healthy Aging / Longevity Stack

The evidence for Healthy Aging / Longevity Stack

Graded by what exists behind each claim.

✅ Clinically validated

• Sold against the mechanisms with the strongest aging-biology rationale. Which of those the box contains on the day it ships is the vendor's decision and is not established on this page.

📊 Correlative data

• A bundle has no epidemiology of its own. Where observational evidence exists it belongs to the individual ingredients and sits on their pages — read it there rather than inferring it for the combination, which nobody has studied as a unit.

🧪 Theoretical / extrapolated benefits

• No bundle has been studied as a unit, so any claim about the combination is extrapolated from the individual components. Where two ingredients share a pathway, additivity is plausible; where they do not, expect independence. Read each component's own page for what is actually predicted of it.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Healthy Aging / Longevity Stack actually does

This box contains four different theories of aging, and the structural point worth making first is that they do not converge. They are not four inputs to one pathway; they are four competing explanations of why cells deteriorate, packaged as though agreeing with all of them at once were a strategy.

Theory one: NAD+ as a consumable. NAD+ is not used catalytically by the enzymes that matter here — it is destroyed. PARP1 cleaves it during DNA repair, CD38 hydrolyzes it and becomes more abundant with age, and the sirtuins split it to transfer an acetyl group. So NAD+ falls because consumption rises, and a precursor addresses that by refilling the pool: nicotinamide riboside enters through nicotinamide riboside kinase to become NMN and then NAD+ via NMNAT. That is a coherent substrate-supply argument and it is the strongest mechanism in the box.

Theory two: sirtuin activation, and the correction nobody prints. Resveratrol became a longevity molecule on the strength of assays showing it allosterically activates SIRT1. Those assays used a substrate peptide carrying a bulky fluorophore, and the activation largely disappeared with a native substrate — the effect was substantially an artifact of the reporter. The compound may still do things; the specific claim that founded the category has not held.

Theory three: senolysis. Senescent cells resist apoptosis by leaning on anti-apoptotic proteins of the BCL-2 family and on tyrosine kinase survival signaling. Dasatinib plus quercetin is proposed to remove that support intermittently, which is why the dosing is a two-or-three-day pulse rather than a daily capsule. Note that a longevity bundle giving quercetin daily is using the senolytic ingredient on the schedule the senolytic hypothesis says will not work.

Theory four: antioxidants — and here the box contains an argument with itself. Mitochondrial reactive oxygen species are not only damage; they are the signal that drives adaptation. Exercise-induced ROS activate the redox-sensitive transcription programs behind mitochondrial biogenesis, and high-dose antioxidant supplementation has blunted training adaptations in controlled trials. A person training hard and taking a large daily antioxidant load is paying to attenuate the intervention with the best longevity evidence there is.

The one place two ingredients truly share a step, and it is a liability. Resveratrol and quercetin are both handled by the same phase-II conjugation enzymes and both inhibit CYP3A4. Their mechanisms of action have nothing in common; their metabolism does, which means each raises the other's exposure and both raise the exposure of any prescription drug on the same enzyme. That is the real interaction inside this bundle, and it points at the medicine cabinet rather than at the mitochondria.

Cell, rodent, human — and where it stops

NAD+ precursors: the human data is real, small and biochemical. Healthy middle-aged and older adults took 1,000 mg/day of nicotinamide riboside for six weeks; it was well tolerated and whole-blood NAD+ rose substantially Martens 2018. That is the anchor trial for the entire NAD+ category, and two things about it must travel with the number. The endpoint was NAD+ in blood, not in muscle, liver or brain. And the dose is 1,000 mg — a longevity bundle carrying 250 or 300 mg of NR or NMN is delivering a quarter to a third of it, at which the NAD+ rise has not been characterized at all.

Resveratrol: the best-designed human trial found nothing. Nonobese women with normal glucose tolerance took resveratrol for 12 weeks with no improvement in insulin sensitivity, mitochondrial function or resting metabolic rate Yoshino 2012. Note the population — metabolically healthy. That is the honest boundary condition on this ingredient: where there is no dysfunction, there is no measurable effect, which is the same shape as every other correction-of-a-deficit story in the Stacks category.

Senolytics: fourteen people, no placebo. The first-in-human senolytic study gave intermittent dasatinib plus quercetin to 14 patients with idiopathic pulmonary fibrosis in an open-label pilot, with physical function as the endpoint Justice 2019. It is a legitimate and important first step and it is not evidence that a healthy person should take quercetin for aging. Every human senolytic dataset to date is in a disease population, small, and mostly unblinded.

The obstacle that decides this entire page. There is no outcome. Not one trial in this category has reported mortality, incident disease or a validated functional endpoint against placebo in healthy adults. The nearest large trial of any ingredient plausibly in a longevity bundle is the vitamin D arm of VITAL — 25,871 people, 5.3 years, no reduction in cancer or cardiovascular events Manson 2019. When the best-powered nutrient trial in this space is null, a bundle of less-studied ingredients should be sold with that stated, not with it omitted.

Healthy Aging / Longevity Stack — which form, and does it matter

NAD+ precursors, and the form question that inverts the marketing. Nicotinamide riboside chloride is the form in the human trial Martens 2018. NMN is a different molecule with a shorter and more contested human record. And plain nicotinamide — the cheapest NAD+ precursor of all — is a product-inhibitor of the sirtuins, the very enzymes the category is sold on. So the least expensive way to raise NAD+ is also the one with a mechanistic argument for working against the stated target, which is worth knowing before comparing prices per gram. Niacin as nicotinic acid raises NAD+ too, and produces the prostaglandin-mediated flush through GPR109A that the other forms avoid.

Resveratrol. The trans isomer is the studied one; the cis form is generated by light and heat and is not what the literature refers to. Oral bioavailability is very low because of near-total glucuronidation and sulfation in gut wall and liver, which is why micronized and piperine-combined preparations exist — and why a milligram figure on a resveratrol label is a poor guide to anything reaching tissue.

Quercetin. The aglycone is poorly absorbed; phytosome and glycoside forms differ several-fold in plasma exposure, so equal milligrams of two quercetin products are not equal doses. The senolytic protocol also differs in schedule rather than form: intermittent pulses, not daily maintenance Justice 2019.

CoQ10 and the rest of the antioxidant arm. Ubiquinol is the reduced form and is better absorbed at equal milligrams than ubiquinone, though ubiquinone in a solubilized oil matrix closes much of that gap and carries most of the trial evidence. For any fat-soluble ingredient here, taking the capsule with a fat-containing meal changes exposure more than switching brands does.

What would have to be true, and how you would know it was not

The central claim of this category cannot be measured in you, so the predictions have to be about the things that can.

1. Whole-blood NAD+ would rise at 1,000 mg/day of NR — and you cannot usefully test it. The trial measured it in a research laboratory Martens 2018. There is no standardized, clinically validated consumer NAD+ assay, results are not comparable between providers, and blood NAD+ is not tissue NAD+ in any case. State that plainly: the mechanism you are paying for is not verifiable in you at any price.

2. So measure the risks that actually shorten healthspan, at baseline and six months. ApoB for atherogenic particle number, hs-CRP for inflammatory load, HbA1c for glycation, homocysteine for the vascular and methylation side. None of them is a claim about this bundle. They are the numbers that predict the outcome the bundle is sold against, which makes them the fairest available verdict on it.

3. Grip strength and a repeatable submaximal effort, recorded the same way, at baseline and six months. Functional endpoints were the outcome in the only human senolytic study Justice 2019, and grip strength is free.

4. The prediction that cuts against the stack, and it is the one I would bet on: none of the four numbers in point 2 will move. There is no mechanism in this box with a demonstrated effect on ApoB or HbA1c in a healthy adult, and the metabolically-healthy resveratrol trial is the closest test anyone has run Yoshino 2012. Six months of no change is not an inconclusive result; it is the result.

5. And one adverse prediction that is genuinely measurable. If the bundle carries gram-scale resveratrol or quercetin and you take a CYP3A4 substrate — several statins, some calcium channel blockers, tacrolimus, apixaban — predict that drug's effect or level rises. That is testable with the monitoring your prescriber already does, and it is the most likely way this stack produces a clinically detectable change in anything.

What nobody has tested yet

Nobody has measured tissue NAD+ in a person taking a consumer longevity bundle. The human data is whole-blood Martens 2018, and the interesting compartments are skeletal muscle, liver and brain. A vastus lateralis biopsy before and after 8 weeks at 1,000 mg/day, 20 people, would tell the field whether the blood number means anything about the tissue. It is invasive, it is routine in exercise physiology, and it has not been done for a commercial product.

The dose-response between 250 mg and 1,000 mg has never been mapped. Commercial bundles sit at the bottom of that range and the only well-documented human NAD+ elevation sits at the top. Three arms, 250, 500 and 1,000 mg/day for 8 weeks, with the same assay, would tell buyers whether the cheaper product is a smaller dose or no dose. That single experiment would reprice half this category.

Nobody has run senolytics in healthy people. Every human dataset is in disease Justice 2019, and the open question is not whether senescent cells can be cleared but whether clearing them in someone without a fibrotic or metabolic disease does anything good — senescence also serves tumor suppression and wound healing, so the direction is genuinely unknown rather than assumed positive.

And the antioxidant-versus-training question has never been asked inside a bundle. Randomize trained adults to the full longevity stack or to placebo across a 12-week progressive program and measure VO2 and mitochondrial markers. If the antioxidant arm blunts adaptation, the bundle is subtracting from the best-evidenced longevity intervention its buyer performs, and the trial to find out is a standard exercise study with a supplement arm bolted on.

Healthy Aging / Longevity Stack — its own safety story, not its category's

The interaction that belongs to the combination rather than to any ingredient. Resveratrol and quercetin both inhibit CYP3A4, and quercetin also inhibits P-glycoprotein. Together, at the gram doses these bundles use, they can raise plasma levels of statins (and with them the myopathy risk), of calcium channel blockers, of tacrolimus and cyclosporine, and of several direct oral anticoagulants. Neither ingredient alone is usually flagged; the combination is a meaningful enzyme inhibition and it is invisible because no label describes the box as a CYP inhibitor.

Bleeding and surgery. Resveratrol, quercetin and high-dose fish oil all have antiplatelet activity, and a longevity bundle frequently contains more than one of them. Stop the box a week before any procedure and tell the anesthetist, because the additive effect is the part nobody adds up.

Niacin, if the NAD+ arm uses it. Immediate-release nicotinic acid flushes; sustained-release forms flush less and carry the hepatotoxicity signal, including cases of fulminant liver failure at gram doses. High-dose niacin also raises fasting glucose and uric acid, which is worth knowing if you are running HbA1c as your read-out.

The NAD+ and cancer question, stated because it is left out. Proliferating cells require NAD+, and NAMPT — the enzyme that regenerates it — is an oncology drug target precisely because inhibiting it starves tumors. Deliberately raising NAD+ availability in someone with an active or recent malignancy is therefore in an unknown direction rather than a safe one. The rodent and cell literature has results pointing both ways and no human trial has addressed it, which is exactly the kind of open question that should be on the page rather than in a footnote.

And the substitution risk, which is the largest hazard here. The interventions with mortality evidence are blood pressure control, apolipoprotein B reduction, not smoking, resistance training and sleep. A stack whose four measurable risk markers are unchanged at six months, taken by someone whose blood pressure has not been checked in two years, has cost far more than its price.

Sources read for this page

• Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults. Nature Communications, 2018 · PMID 29599478
• Yoshino J, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metabolism, 2012 · PMID 23102619
• Justice JN, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine, 2019 · PMID 30616998
• Manson JE, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. The New England Journal of Medicine, 2019 · PMID 30415629

How you would know if it worked

Healthy Aging / Longevity Stack — safety & side effects

Bloodwork to run alongside Healthy Aging / Longevity Stack

Baseline first, then again at 8–12 weeks.

The Basics — Start Here panel covers these in one order — 4 markers, $32.40 with the discount applied.

Check results you already have → · All 103 markers A–Z

Healthy Aging / Longevity Stack — frequently asked questions

Healthy Aging / Longevity Stack inside a finished plan

One arm of 1 Protocol Blueprint, free to read in full.

What Healthy Aging / Longevity Stack is used for

Healthy Aging / Longevity Stack appears under 1 goal in the goal router.

Related Stacks & Bundles supplements

← Browse the full Supplement Vault

↑ Back to on this page